TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28081351

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 15 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 5 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 25053420

Group type: EXPERIMENTAL
Intervention: Stopping breastfeeding before 6 months
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Low birthweight
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Maternal completion of high school education
Number of subjects: 964
Study: 22162533

Group type: EXPERIMENTAL
Intervention: Istradefylline (20 to 40 mg/d)
Number of subjects: 1760

Group type: EXPERIMENTAL
Intervention: Istradefylline (40 mg/d)
Number of subjects: 1760

Group type: EXPERIMENTAL
Intervention: Istradefylline (dose increase)
Number of subjects: 1760
Study: 20093065

Group type: EXPERIMENTAL
Intervention: Grade III postero-anterior rotatory joint mobilisation technique applied to T4 at a frequency of 0.5 Hz
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 36
Study: 18555813

Group type: EXPERIMENTAL
Intervention: Drospirenone 3 mg / Ethinylestradiol 20 mcg in a 24/4 regimen
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional 21/7 regimen
Number of subjects: 104
Study: 15756154

Group type: EXPERIMENTAL
Intervention: Epidural administration of naropina 0.2%+fentanyl 4 microg/mL by elastomeric pump (rate 5 ml/h)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Continuous infusion of tramadol 600 mg+ketorolac trometamina 120 mg+ranitidina 200 mg+ondansetron 16 mg by elastomeric pump (rate 5 ml/h for 48 hours)
Number of subjects: 50
Study: 12427649

Group type: EXPERIMENTAL
Intervention: simvastatin
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: simvastatin plus 600 mg/d vitamin E
Number of subjects: 43
Study: 10320598

Group type: EXPERIMENTAL
Intervention: Paracetamol elixir (40 mg x kg(‐1)) 90 min before surgery
Number of subjects: 81

Group type: COMPARATOR
Intervention: Paracetamol suppositories (40 mg x kg(‐1)) intraoperatively
Number of subjects: 81
Study: 7588352

Group type: EXPERIMENTAL
Intervention: Fluconazole (3 mg/kg/daily per os)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flucytosine (100 mg/kg/daily per os)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 1790034

Group type: EXPERIMENTAL
Intervention: Minimal interactional intervention
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Maximal interactional intervention
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Both interventions combined
Number of subjects: 202
Study: 6794145

Group type: EXPERIMENTAL
Intervention: Fluproquazone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 48
Study: 30957170

Group type: EXPERIMENTAL
Intervention: 8 weeks of grazoprevir/elbasvir therapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: 12 weeks of grazoprevir/elbasvir therapy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 8 weeks of grazoprevir/elbasvir therapy with high HCV-1b load (≥1,500,000 IU/mL)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 8 weeks of grazoprevir/elbasvir therapy with baseline Y93H RAS frequency >15%
Number of subjects: 82

Group type: COMPARATOR
Intervention: 12 weeks of grazoprevir/elbasvir therapy with high HCV-1b load and baseline Y93H RAS frequency >15%
Number of subjects: 82
Study: 26596997

Group type: EXPERIMENTAL
Intervention: Family Meal Intervention (FMI)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Family Therapy with Family Meal Intervention (FTFM)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Family Therapy without Family Meal Intervention (FT)
Number of subjects: 23
Study: 25722378

Group type: EXPERIMENTAL
Intervention: Strength training (S; n = 24)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Endurance training (E; n = 26)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combined strength + endurance training (SE; n = 24)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Physical activity recommendations (C; n = 22)
Number of subjects: 96
Study: 23420115

Group type: EXPERIMENTAL
Intervention: Theobromine 250 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Theobromine 500 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Theobromine 1000 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Caffeine 200 mg
Number of subjects: 80
Study: 21536693

Group type: EXPERIMENTAL
Intervention: Switch to monotherapy
Number of subjects: 127

Group type: COMPARATOR
Intervention: Stay on polypharmacy
Number of subjects: 127
Study: 19401662

Group type: EXPERIMENTAL
Intervention: Increased systolic blood pressure (from 105 ± 10 to 135 ± 14 mmHg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Increased tidal volume (from 6 to 10 ml kg(‐1))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 16
Study: 16963248

Group type: EXPERIMENTAL
Intervention: High-dose purified soy isoflavones (genistein, 558 mg/day; daidzein, 296 mg/day; glycitein, 44 mg/day) for 84 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-dose purified soy isoflavones
Number of subjects: 30
Study: 15783119

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) 300 mg with pyridoxine 20 mg daily for 1 year or until TB development
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no INH prophylaxis)
Number of subjects: 90
Study: 11522468

Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9926498

Group type: EXPERIMENTAL
Intervention: Interactive activity-based program implemented in local elementary schools
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 7873469

Group type: EXPERIMENTAL
Intervention: Long-acting nitrates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockers or calcium antagonists (used in association with nitrates)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 3348157

Group type: EXPERIMENTAL
Intervention: Multivitamin-mineral supplement providing 0.5 mg/d vitamin B-6
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups (supplemented and placebo)
Number of subjects: 23
Study: 31550352

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (ASI) 50 units
Number of subjects: 184
Study: 30871936

Group type: EXPERIMENTAL
Intervention: Wondaleaf‐Cap® (WLC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Wondaleaf‐On‐Man® (WLM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Durex®‐Together (DT)
Number of subjects: 50
Study: 28442892

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg orodispersible film
Number of subjects: 53

Group type: COMPARATOR
Intervention: Film-coated 100 mg tablet (Viagra®)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Both formulations
Number of subjects: 53
Study: 25487006

Group type: EXPERIMENTAL
Intervention: Manual pressure before benzathine penicillin injection
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard injection technique
Number of subjects: 51
Study: 23180210

Group type: EXPERIMENTAL
Intervention: Interval training (INT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eucaloric steady state aerobic training (AER)
Number of subjects: 0
Study: 20887742

Group type: EXPERIMENTAL
Intervention: Protein-rich supplements (80±21g protein intake)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Isoenergetic combination of carbohydrate and fat supplements (59±11g protein intake)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Protein-rich supplements
Number of subjects: 24

Group type: COMPARATOR
Intervention: Isoenergetic combination of carbohydrate and fat supplements
Number of subjects: 24
Study: 19202626

Group type: EXPERIMENTAL
Intervention: Nootropil
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Nootropil (Control)
Number of subjects: 0
Study: 16791663

Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Active heat and moisture exchanger
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Heated humidifier
Number of subjects: 9
Study: 14508205

Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Lercanidipine (20 mg daily)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Lercanidipine
Number of subjects: 22
Study: 11025232

Group type: EXPERIMENTAL
Intervention: Clonidine 3 microg/kg IV
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 8619389

Group type: EXPERIMENTAL
Intervention: Estrogen plus UFT (400 mg/day: group B)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Estrogen alone (Honvan 200 mg/day or presexol 1 mg/day: group A)
Number of subjects: 34
Study: 1443954

Group type: EXPERIMENTAL
Intervention: Absolute event data
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Relative risk reductions
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Trial reporting 77 persons treated for 5 years to prevent one myocardial infarction
Number of subjects: 100
Study: 4015740

Group type: EXPERIMENTAL
Intervention: Suprofen 200 mg/ml i.m. (3 injections/day for 7 days)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Diclofenac 25 mg/ml i.m. (3 injections/day for 7 days)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (3 injections/day for 7 days)
Number of subjects: 45
Study: 31272477

Group type: EXPERIMENTAL
Intervention: Antipsychotics (APs) alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Psychological Interventions (PI) alone (Cognitive Behavioural Therapy and Family Intervention)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of Antipsychotics and Psychological Interventions
Number of subjects: 90
Study: 30058395

Group type: EXPERIMENTAL
Intervention: Dialectical Behavioral Therapy‐Corrections Modified (DBT‐CM)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Health Promotion (HP) program
Number of subjects: 130
Study: 26863321

Group type: EXPERIMENTAL
Intervention: Yoga intervention (10 sessions)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Yoga practice frequency after treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (seminar in women's health)
Number of subjects: 49
Study: 23389831

Group type: COMPARATOR
Intervention: Helicopter transport
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Ground transport
Number of subjects: 330

Group type: COMPARATOR
Intervention: Modified Rankin Scale at 3 months
Number of subjects: 330

Group type: COMPARATOR
Intervention: 30-day mortality
Number of subjects: 330

Group type: COMPARATOR
Intervention: 1-year mortality
Number of subjects: 330
Study: 22157329

Group type: EXPERIMENTAL
Intervention: Acotiamide 100 mg three times a day for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acotiamide 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acotiamide and Placebo
Number of subjects: 0
Study: 19825809

Group type: EXPERIMENTAL
Intervention: Baseline haemoglobin levels
Number of subjects: 32170
Study: 16959907

Group type: EXPERIMENTAL
Intervention: Acute heavy resistance exercise protocol (AHREP; 6 x 10 repetitions parallel squats, 80% 1 repetition maximum)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (Cont; rest)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: AHREP (F(maintainers))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: AHREP (F(reducers))
Number of subjects: 10
Study: 15816570

Group type: EXPERIMENTAL
Intervention: Group A: 3 mL demand dose with 6 min lockout interval
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Group B: 6 mL demand dose with 12 min lockout interval
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Group C: 9 mL demand dose with 18 min lockout interval
Number of subjects: 84
Study: 12774848

Group type: EXPERIMENTAL
Intervention: Red wine (400 mL, 279.6 mg total anthocyanins)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Red grape juice (400 mL, 283.5 mg total anthocyanins)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Red wine anthocyanins
Number of subjects: 9

Group type: COMPARATOR
Intervention: Red grape juice anthocyanins
Number of subjects: 9
Study: 10563230

Group type: EXPERIMENTAL
Intervention: Prophylactic drugs (metoprolol, divalproex, amitriptyline, atenolol, flunarizine, naproxen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8740095

Group type: COMPARATOR
Intervention: 200 mg cefpodoxime proxetil (reference)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 mg cefpodoxime and 200 mg acetylcysteine (test)
Number of subjects: 12
Study: 1923440

Group type: EXPERIMENTAL
Intervention: Listerine Antiseptic (LA) rinse
Number of subjects: 96

Group type: COMPARATOR
Intervention: Hydroalcoholic control rinse
Number of subjects: 96
Study: 6622240

Group type: EXPERIMENTAL
Intervention: Re-usable temporary one-size prosthesis of endoskeletal type with adjustable tube length, training started 2-4 weeks after amputation and lasted for 1-4 weeks.
Number of subjects: 95
Study: 31367995

Group type: EXPERIMENTAL
Intervention: Audiovisual information via a video depicting miniscrew application (study group, 44 patients)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Verbal information about the procedure (control group, 44 patients)
Number of subjects: 88
Study: 29864037

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 74
Study: 27044360

Group type: EXPERIMENTAL
Intervention: Health TAPESTRY approach
Number of subjects: 316

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 316
Study: 24147869

Group type: EXPERIMENTAL
Intervention: On-demand alverine citrate/simeticone (ACS) treatment
Number of subjects: 436

Group type: COMPARATOR
Intervention: Usual treatment (mainly antispasmodics)
Number of subjects: 436
Study: 22231417

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (BoNT‐ONA; Botox)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: abobotulinumtoxinA (BoNT‐ABO; Dysport)
Number of subjects: 53
Study: 21147706

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (300,000 IU ergocalciferol, 4 times/year)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 50
Study: 18179286

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Minimal support control condition
Number of subjects: 134
Study: 15574551

Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) KIU loading dose, 2 x 10(6) KIU added to circuit prime, continuous infusion of 5 x 10(5) KIU/hr)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 11264758

Group type: EXPERIMENTAL
Intervention: Pranlukast
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 9832483

Group type: COMPARATOR
Intervention: Control diet (low in fruits, vegetables, and dairy products, 37% of calories from fat)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Fruits and vegetables diet (rich in fruits and vegetables, otherwise similar to control diet)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Combination diet (rich in fruits, vegetables, and low-fat dairy products, reduced in fat)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Fruits and vegetables diet
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Combination diet
Number of subjects: 123
Study: 8126691

Group type: EXPERIMENTAL
Intervention: Disclosure induction (three weekly 20-min individual sessions discussing a stressful topic)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 76
Study: 2508791

Group type: EXPERIMENTAL
Intervention: DDAVP (0.3 microgram/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cryoprecipitate
Number of subjects: 10
Study: 412099

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (150 mg of trimethoprim and 750 mg of sulfamethoxazole per square meter per day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 160
Study: 30476131

Group type: EXPERIMENTAL
Intervention: Genetically elevated C-reactive protein (CRP) concentration
Number of subjects: 30580

Group type: EXPERIMENTAL
Intervention: CRP-associated SNPs (rs1260326 and rs6734238)
Number of subjects: 30580
Study: 27836905

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (CFNB) with ropivacaine infusion for 2 days and oxycodone
Number of subjects: 74

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesic (IV PCA) of morphine
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (CFNB)
Number of subjects: 74
Study: 26070650

Group type: EXPERIMENTAL
Intervention: Pain education (intervention group)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Sham education (control group)
Number of subjects: 202
Study: 23771842

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with low-income patients managing diabetes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Strategic attempts at incorporating healthy dietary practices
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Health care provider recommendations
Number of subjects: 20
Study: 21672204

Group type: EXPERIMENTAL
Intervention: Multivitamin-mineral supplement
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Post-trial survey
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Unmasking offer
Number of subjects: 817
Study: 19928391

Group type: EXPERIMENTAL
Intervention: 2 mg/kg of MDMA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sleep restriction (positive control)
Number of subjects: 20
Study: 16739854

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 15

Group type: COMPARATOR
Intervention: No acupuncture (Control)
Number of subjects: 15
Study: 15217028

Group type: EXPERIMENTAL
Intervention: Telephone-based problem-solving therapy
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Telephone-based stress-management training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 54
Study: 12539568

Group type: EXPERIMENTAL
Intervention: Propofol (0.1 mg.kg‐1.min‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fentanyl (5 micrograms.kg‐1.min‐1)
Number of subjects: 30
Study: 9416719

Group type: EXPERIMENTAL
Intervention: Patient-controlled interscalene analgesia (PCIA) with 0.15% bupivacaine, continuous infusion at 5 ml/h plus bolus of 3 or 4 ml with a lock-time of 20 min.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (PCA) with nicomorphine, continuous infusion at 0.5 mg/h plus bolus of 2 or 3 mg with a lock-time of 20 min.
Number of subjects: 40
Study: 8233295

Group type: EXPERIMENTAL
Intervention: CVM (carboplatin/vinblastine/methotrexate)
Number of subjects: 104

Group type: COMPARATOR
Intervention: ACE (doxorubicin/cyclophosphamide/etoposide)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: CVM
Number of subjects: 104

Group type: COMPARATOR
Intervention: ACE
Number of subjects: 104
Study: 3815837

Group type: EXPERIMENTAL
Intervention: High dose Bupivacaine (50 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low dose Bupivacaine (25 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oxytocin administration during the block
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both doses of Bupivacaine
Number of subjects: 60
Study: 30556233

Group type: EXPERIMENTAL
Intervention: Wheelchair-bound Senior Elastic Band exercise program (3 times per week, 40 min per session for 6 months)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Wheelchair-bound Senior Elastic Band exercise program
Number of subjects: 133
Study: 28821427

Group type: EXPERIMENTAL
Intervention: Strength training one time per week (EX1)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Strength training two times per week (EX2)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Strength training three times per week (EX3)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Non-training control group (CON)
Number of subjects: 106
Study: 25575620

Group type: EXPERIMENTAL
Intervention: LSD (200 μg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 23168399

Group type: EXPERIMENTAL
Intervention: Muscle Resistance Program (MRP) at 75% of maximum load, 10 weeks, 3 times/week
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cessation of Muscle Resistance Program (MRP) after 10 weeks
Number of subjects: 32
Study: 20980126

Group type: EXPERIMENTAL
Intervention: Attention modification paradigm designed to influence selective engagement with threat meanings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention modification paradigm designed to influence selective disengagement from threat meanings
Number of subjects: 0
Study: 18089634

Group type: EXPERIMENTAL
Intervention: Pamidronate 12 mg/kg/year
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pamidronate 6 mg/kg/year
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pamidronate (both doses)
Number of subjects: 12
Study: 16968913

Group type: EXPERIMENTAL
Intervention: Primaquine phosphate (30 mg base daily for 14 days for PART; 30 mg daily for primary prophylaxis)
Number of subjects: 0
Study: 15248876

Group type: EXPERIMENTAL
Intervention: IMZ implants
Number of subjects: 61

Group type: COMPARATOR
Intervention: Brånemark implants
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both IMZ and Brånemark implants
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Prosthetic revisions
Number of subjects: 61
Study: 11335737

Group type: EXPERIMENTAL
Intervention: Room air resuscitation (RAR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 100% oxygen resuscitation (OxR)
Number of subjects: 0
Study: 9352971

Group type: EXPERIMENTAL
Intervention: Intravenous conjugated estrogens (0.625 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20